Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.

Macklin EA, Blacker D, Hyman BT, Betensky RA.

J Alzheimers Dis. 2013;36(3):475-86. doi: 10.3233/JAD-122212.

2.

Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.

Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins RN, Maruff P, Masters CL, Romano G, Rowe CC, Savage G, Macaulay SL, Narayan VA; Alzheimer’s Disease Neuroimaging Initiative; AIBL Research Group.

J Alzheimers Dis. 2015;46(4):1079-89. doi: 10.3233/JAD-143015.

PMID:
26402634
3.

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM.

Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4.

5.
6.

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.

Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S45-55. doi: 10.1016/j.jalz.2011.11.002. Epub 2012 Jun 1.

PMID:
22658286
7.

Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores.

Williams MM, Storandt M, Roe CM, Morris JC.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S39-44. doi: 10.1016/j.jalz.2012.01.005. Epub 2012 Aug 1.

8.

Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.

Hallikainen I, Hänninen T, Fraunberg M, Hongisto K, Välimäki T, Hiltunen A, Karppi P, Sivenius J, Soininen H, Koivisto AM; ALSOVA study group.

Int Psychogeriatr. 2013 Aug;25(8):1335-44. doi: 10.1017/S1041610213000653. Epub 2013 May 16.

PMID:
23676340
9.

Effect of study partner on the conduct of Alzheimer disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J.

Neurology. 2013 Jan 15;80(3):282-8. doi: 10.1212/WNL.0b013e31827debfe. Epub 2012 Dec 19.

10.

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BN, Simmons A, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Muscio C, Herukka SK, Salmon E, Bastin C, Wallin A, Nordlund A, de Mendonça A, Silva D, Santana I, Lemos R, Engelborghs S, Van der Mussele S; Alzheimer’s Disease Neuroimaging Initiative, Freund-Levi Y, Wallin ÅK, Hampel H, van der Flier W, Scheltens P, Visser PJ.

Brain. 2015 May;138(Pt 5):1327-38. doi: 10.1093/brain/awv029. Epub 2015 Feb 17.

11.

Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Morris JC.

Arch Neurol. 2012 Jun;69(6):700-8. doi: 10.1001/archneurol.2011.3152.

12.

Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.

Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B.

Alzheimers Dement. 2011 Nov;7(6):602-610.e2. doi: 10.1016/j.jalz.2011.01.005. Epub 2011 Jul 13.

PMID:
21745761
13.

Biomarkers in Alzheimer's disease: not yet surrogate endpoints.

Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B.

Ann N Y Acad Sci. 2009 Oct;1180:119-24. doi: 10.1111/j.1749-6632.2009.04947.x.

PMID:
19906266
14.

Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.

Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M.

J Intern Med. 2014 Mar;275(3):304-16. doi: 10.1111/joim.12167.

15.

Measuring cognitive change in subjects with prodromal Alzheimer's disease.

Mura T, Proust-Lima C, Jacqmin-Gadda H, Akbaraly TN, Touchon J, Dubois B, Berr C.

J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):363-70. doi: 10.1136/jnnp-2013-305078. Epub 2013 Jul 9.

PMID:
23840054
16.

The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.

Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S21-31. doi: 10.1016/j.jalz.2012.05.2187. Epub 2012 Nov 2.

17.

Development of a straightforward and sensitive scale for MCI and early AD clinical trials.

Huang Y, Ito K, Billing CB Jr, Anziano RJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Apr;11(4):404-14. doi: 10.1016/j.jalz.2014.03.008. Epub 2014 Jul 9.

PMID:
25022537
18.

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins PV, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG.

Am J Geriatr Psychiatry. 2011 Jun;19(6):532-42. doi: 10.1097/JGP.0b013e3181faec23.

19.

Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.

Bernick C, Cummings J, Raman R, Sun X, Aisen P.

Arch Neurol. 2012 Jul;69(7):901-5.

PMID:
22431834
20.

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.

Langbaum JB, Hendrix SB, Ayutyanont N, Chen K, Fleisher AS, Shah RC, Barnes LL, Bennett DA, Tariot PN, Reiman EM.

Alzheimers Dement. 2014 Nov;10(6):666-74. doi: 10.1016/j.jalz.2014.02.002. Epub 2014 Apr 21.

Items per page

Supplemental Content

Write to the Help Desk